ATE362755T1 - Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen - Google Patents

Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen

Info

Publication number
ATE362755T1
ATE362755T1 AT96930344T AT96930344T ATE362755T1 AT E362755 T1 ATE362755 T1 AT E362755T1 AT 96930344 T AT96930344 T AT 96930344T AT 96930344 T AT96930344 T AT 96930344T AT E362755 T1 ATE362755 T1 AT E362755T1
Authority
AT
Austria
Prior art keywords
pct
propargyl
aminoindane
compositions containing
stable compositions
Prior art date
Application number
AT96930344T
Other languages
German (de)
English (en)
Inventor
Peskin Tirtsah Berger
Fanny Caciularu
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE362755(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE362755T1 publication Critical patent/ATE362755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
AT96930344T 1995-09-20 1996-09-18 Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen ATE362755T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols

Publications (1)

Publication Number Publication Date
ATE362755T1 true ATE362755T1 (de) 2007-06-15

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930344T ATE362755T1 (de) 1995-09-20 1996-09-18 Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen

Country Status (13)

Country Link
US (1) US6126968A (cg-RX-API-DMAC7.html)
EP (1) EP0858328B1 (cg-RX-API-DMAC7.html)
JP (1) JP4108750B2 (cg-RX-API-DMAC7.html)
AT (1) ATE362755T1 (cg-RX-API-DMAC7.html)
AU (1) AU728524B2 (cg-RX-API-DMAC7.html)
CA (1) CA2232310C (cg-RX-API-DMAC7.html)
DE (1) DE69637096T2 (cg-RX-API-DMAC7.html)
DK (1) DK0858328T3 (cg-RX-API-DMAC7.html)
ES (1) ES2287940T3 (cg-RX-API-DMAC7.html)
HU (1) HU225859B1 (cg-RX-API-DMAC7.html)
IL (1) IL115357A (cg-RX-API-DMAC7.html)
PT (1) PT858328E (cg-RX-API-DMAC7.html)
WO (1) WO1997012583A2 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU775885B2 (en) 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
ATE365546T1 (de) * 2004-11-10 2007-07-15 Teva Pharma Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP2009518433A (ja) 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
AU2007217349B9 (en) 2006-02-21 2013-06-27 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Multiple System Atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EA016843B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR20100107028A (ko) * 2008-01-11 2010-10-04 테바 파마슈티컬 인더스트리즈 리미티드 라사길린 제형, 그들의 제법 및 용도
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
US7968749B2 (en) * 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
CN102341104A (zh) 2009-03-05 2012-02-01 桑多斯股份公司 含有甲磺酸雷沙吉兰的药物组合物
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
MX2012007375A (es) 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
CN108186611A (zh) 2010-04-30 2018-06-22 帝国制药美国公司 丙炔基氨基茚满透皮组合物
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
BR112014008555A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
ES2584059T3 (es) 2012-03-21 2016-09-23 Synthon Bv Composiciones farmacéuticas estabilizadas que comprenden sales de rasagilina
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
EP2764862A1 (en) * 2013-02-06 2014-08-13 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
EE04039B1 (et) * 1995-03-02 2003-06-16 R.P. Scherer Limited Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine

Also Published As

Publication number Publication date
EP0858328A4 (en) 2001-07-11
DE69637096T2 (de) 2008-01-31
AU728524B2 (en) 2001-01-11
WO1997012583A3 (en) 1997-06-05
WO1997012583A2 (en) 1997-04-10
HU225859B1 (en) 2007-11-28
PT858328E (pt) 2007-08-20
IL115357A0 (en) 1995-12-31
CA2232310C (en) 2008-01-08
US6126968A (en) 2000-10-03
DE69637096D1 (de) 2007-07-05
HUP9802999A2 (hu) 1999-04-28
EP0858328A2 (en) 1998-08-19
JP4108750B2 (ja) 2008-06-25
ES2287940T3 (es) 2007-12-16
DK0858328T3 (da) 2007-09-03
EP0858328B1 (en) 2007-05-23
JPH11512736A (ja) 1999-11-02
AU6942796A (en) 1997-04-28
IL115357A (en) 2000-01-31
CA2232310A1 (en) 1997-04-10
HUP9802999A3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
ATE362755T1 (de) Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
BR9407239A (pt) Azadioxacicloalquenos substituídos
ZA948670B (en) New benzoyl guanidine derivatives,the preparation thereof and their use in pharmaceutical compositions
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IT1272149B (it) Composizione farmeceutiche ad attivita' analgesica
CA2152998A1 (en) Anti-hyperglycemia pharmaceutical composition
ATE246515T1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
ES2078175A1 (es) Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
AU2774292A (en) Toiletries composition
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
AU7470098A (en) Antithrombotic agents
ZA965749B (en) Use of allylamines.
KR950700743A (ko) 프로스타사이클린류를 활성성분으로서 함유하는 외용 피부치료제 조성물(dermatologic preparation composition containing prostacyclin as active ingredient)
SI0805817T1 (cg-RX-API-DMAC7.html)
AU7274198A (en) Antithrombotic agents
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
JO1750B1 (en) Substituted benzimidazole compounds, practical to prepare and use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858328

Country of ref document: EP